annb0t
Top 20
Immutep Limited (NASDAQ: IMMP) has received constructive feedback from the FDA regarding its clinical development program for eftilagimod alpha (efti or IMP321) in metastatic breast cancer (MBC).
The agency has supported Immutep's view to continue exploring the development of efti in MBC in a new registrational trial. The FDA's feedback was based on clinical data presented by Immutep, including final overall survival data from its Phase 2b AIPAC trial. Final overall survival (OS) data showed th...
>>> Read more: FDA Backs Immutep's Eftilagimod Registrational Trial In Metastatic Breast Cancer
The agency has supported Immutep's view to continue exploring the development of efti in MBC in a new registrational trial. The FDA's feedback was based on clinical data presented by Immutep, including final overall survival data from its Phase 2b AIPAC trial. Final overall survival (OS) data showed th...
>>> Read more: FDA Backs Immutep's Eftilagimod Registrational Trial In Metastatic Breast Cancer
